Rate Hike Fears: 4 Low-Beta Healthcare Stocks to Buy
💡 Key Takeaway
With rate hike fears resurfacing, low-beta healthcare stocks with strong earnings growth provide a defensive yet growth-oriented investment opportunity.
Renewed Rate Hike Fears Drive Investors to Defensive Sectors
Recent economic data and hawkish Fed commentary have reignited fears of another interest rate hike, causing volatility in the stock market. Investors are increasingly concerned that persistent inflation could force the Federal Reserve to tighten monetary policy further, potentially slowing economic growth and pressuring high-valuation growth stocks.
In this environment, low-beta healthcare stocks are gaining attention for their defensive characteristics. These companies typically exhibit lower volatility compared to the broader market, as demand for healthcare products and services remains relatively stable regardless of economic cycles. The four stocks highlighted—ABT, CORT, PGEN, and BHC—combine low beta with strong earnings growth prospects, making them attractive in a rising rate environment.
Abbott Laboratories (ABT) offers a beta of 0.59 and is expected to grow earnings by 7.2%. Corcept Therapeutics (CORT) and Precigen (PGEN) both boast expected earnings growth exceeding 100%, while BHC (Bausch Health Companies) has the lowest beta at 0.37 and 16.6% earnings growth. All four carry favorable Zacks ranks, indicating positive analyst sentiment.
Why Low-Beta Healthcare Stocks Shine When Rates Rise
When interest rates rise, growth stocks often suffer as higher discount rates reduce the present value of future earnings. However, low-beta healthcare stocks tend to be less sensitive to market swings and offer essential products, providing a cushion during turbulent times. Their stable cash flows and inelastic demand make them a safe haven for investors seeking to reduce portfolio volatility.
Moreover, the healthcare sector is less cyclical than consumer discretionary or technology, so it can outperform when economic growth slows. The stocks mentioned also have strong earnings growth trajectories, which can help offset the negative impact of higher rates. For instance, CORT and PGEN are expected to deliver triple-digit earnings growth, which could drive their stock prices higher even if the broader market struggles.
From a portfolio perspective, adding low-beta healthcare stocks can improve risk-adjusted returns. They may not soar during bull markets, but they tend to hold up better during corrections, making them ideal for conservative investors or those looking to hedge against a potential rate hike-induced selloff.
Source: Zacks Investment Research
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
While rate hike fears may pressure the broader market, low-beta healthcare stocks offer a defensive tilt with growth potential, making them a smart addition to portfolios.
The macro trajectory remains uncertain, with the Fed's next move dependent on incoming data. In this environment, low-beta healthcare stocks provide a balance of stability and growth, but investors should remain cautious and diversified. These stocks are not immune to market downturns, but their defensive characteristics can help mitigate risks.
What This Means for Me
